Green Tea Compound EGCG Shows Promise Against Uterine Fibroids
EGCG, the key polyphenol in green tea, inhibits fibroid growth and may offer a safe, non-invasive alternative to surgery for uterine myomas.
Summary
Uterine fibroids are the most common benign tumors of the female reproductive system, often requiring surgery or hormone therapy. EGCG, the primary bioactive polyphenol in green tea, has demonstrated the ability to inhibit fibroid cell proliferation and induce apoptosis in both lab and clinical settings. A multicenter prospective trial (FRIEND study, 200 women) is currently underway. Early clinical results combining EGCG with vitamin D and B vitamins show a positive effect on reducing fibroid size and relieving symptoms such as heavy menstrual bleeding, pain, and fertility disorders. Researchers argue EGCG represents a promising, well-tolerated, non-invasive treatment option worth serious clinical consideration.
Detailed Summary
Uterine fibroids affect a significant proportion of women of reproductive age, causing heavy menstrual bleeding, pelvic pain, and fertility challenges. Current treatments range from hormonal medications to minimally invasive procedures and surgery, but many carry side effects or compromise uterine preservation. This review explores EGCG as a novel, plant-derived alternative.
EGCG is the most abundant and biologically active catechin found in green tea (Camellia sinensis). It has established anti-tumor properties, including inhibition of cell proliferation and induction of apoptosis in both malignant and benign tumor cells. The authors review evidence that these mechanisms apply specifically to uterine myoma cells.
Preclinical data from in vitro and in vivo studies consistently show EGCG reduces fibroid cell growth. Early clinical trials have added to this picture, with recently published results indicating that EGCG — particularly when combined with vitamin D and B vitamins — safely reduces fibroid size and alleviates associated symptoms without significant adverse effects.
The ongoing FRIEND study, a multicenter prospective trial enrolling 200 women with confirmed uterine myomas, is expected to provide more robust clinical evidence. This trial represents an important step toward establishing EGCG as a standard non-invasive treatment option.
While findings are encouraging, this paper is a review based solely on existing in vitro, in vivo, and early-phase clinical data. Larger randomized controlled trials are still needed to confirm efficacy, optimal dosing, and long-term safety before EGCG can be widely recommended in clinical practice.
Key Findings
- EGCG inhibits uterine fibroid cell proliferation and induces apoptosis in vitro and in vivo.
- Clinical trials combining EGCG with vitamin D and B vitamins show fibroid size reduction and symptom relief.
- EGCG appears safe and well-tolerated based on available clinical trial data.
- The multicenter FRIEND study (200 women) is ongoing and will provide stronger evidence.
- EGCG may address fibroid symptoms including heavy bleeding, pain, and fertility disorders non-invasively.
Methodology
This is a narrative review summarizing preclinical (in vitro and in vivo) and clinical trial data on EGCG's effects on uterine myomas. The authors also reference the ongoing multicenter prospective FRIEND study. No original experimental data were generated by the authors.
Study Limitations
This paper is a review limited to abstract-level synthesis, so granular data on dosing, trial designs, and outcome measures are unavailable. The evidence base remains early-stage, with the pivotal FRIEND trial still ongoing. Publication bias toward positive findings in polyphenol research should also be considered.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: